MAHA anemia, short for microangiopathic hemolytic anemia, is anemia caused by red blood cells being physically torn apart as they squeeze through damaged small blood vessels. It is not a disease on its own but a sign that something else, such as thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or malignant hypertension, is injuring the microcirculation. Because several of those causes are emergencies, finding MAHA on a blood smear should prompt a fast, organized search for the trigger.
What Is MAHA Anemia?
MAHA belongs to the larger family of hemolytic anemias, where red cells are destroyed faster than the bone marrow can replace them. What sets it apart is the mechanism: the damage is mechanical, not immune. Red cells meet strands of fibrin or clumps of platelets inside small vessels and are sliced into fragments.
Those fragments are called schistocytes, and they are the visual signature of MAHA under the microscope. Healthy erythrocytes are flexible discs that normally survive about 120 days. Fragmented cells are rigid and are cleared by the spleen within a short time, so the red cell count falls.
MAHA often travels with a low platelet count, because the same process that shreds red cells also consumes platelets in tiny clots. Doctors group this combination under the term thrombotic microangiopathy (TMA). It sits among the broader hematologic disorders but frequently involves the kidneys, brain, and other organs.
Causes and Risk Factors
How the Damage Happens
The common thread is injury to the endothelium, the thin lining of blood vessels. When endothelial cells are damaged or activated, they encourage platelets to stick and fibrin to form, narrowing the vessel. Red cells pushed through these partial blockages under pressure are cut into pieces.
Main Conditions That Cause MAHA
| Cause | Key mechanism | Typical clues |
|---|---|---|
| Thrombotic thrombocytopenic purpura (TTP) | Severe deficiency of the enzyme ADAMTS13, usually from an autoantibody, leaving ultra-large von Willebrand factor that builds platelet clots | Very low platelets, neurologic symptoms, fever, variable kidney injury |
| Shiga toxin HUS | Toxin from certain E. coli strains injures kidney vessels | Bloody diarrhea a few days earlier, acute kidney injury, most often in children |
| Atypical HUS | Uncontrolled activation of the complement system | Kidney injury without a diarrheal trigger, may recur |
| Disseminated intravascular coagulation (DIC) | Widespread clotting activation from sepsis, trauma, or cancer | Prolonged PT and aPTT, low fibrinogen |
| Malignant hypertension | Extremely high pressure injures arterioles | Severe blood pressure elevation, kidney and eye changes |
| Pregnancy-related (HELLP, preeclampsia) | Placental and endothelial dysfunction | Late pregnancy or postpartum, raised liver enzymes |
| Drugs and transplant | Direct endothelial toxicity | Quinine, calcineurin inhibitors, some chemotherapy agents |
Other contributors include systemic lupus erythematosus, scleroderma renal crisis, and widespread cancer. Mechanical heart valves can also fragment red cells, although that is usually classified separately as a large-vessel or cardiac cause rather than true microangiopathy.
Symptoms of MAHA Anemia
The anemia itself produces familiar complaints: fatigue, pallor, shortness of breath on exertion, and a fast heart rate. Destruction of red cells releases bilirubin, so some people notice mild jaundice or dark urine.
The more worrying symptoms come from the underlying cause and the organs it affects:
- Kidneys: reduced urine output, swelling, rising creatinine.
- Brain: headache, confusion, speech difficulty, weakness, or seizures, especially in TTP.
- Skin: small red or purple spots (petechiae) and easy bruising from low platelets.
- Gut: abdominal pain or bloody diarrhea in Shiga toxin HUS.
In my practice, the combination of new anemia, low platelets, and any neurologic change is treated as TTP until proven otherwise, because delay can be fatal.
How MAHA Anemia Is Diagnosed
Diagnosis has two steps: confirm that red cells are being mechanically destroyed, then identify why. A structured hemolytic anemia workup covers both.
| Test | Typical finding in MAHA | Why it matters |
|---|---|---|
| Complete blood count | Low hemoglobin, often low platelets | Confirms anemia and thrombocytopenia |
| Peripheral blood smear | Schistocytes present | The defining feature of MAHA |
| Reticulocyte count | Raised | Shows the marrow is trying to compensate |
| Lactate dehydrogenase (LDH) | Raised | Released from destroyed cells and injured tissue |
| Haptoglobin | Low or undetectable | Consumed as it binds free hemoglobin |
| Indirect bilirubin | Raised | Breakdown product of hemoglobin |
| Direct antiglobulin test (DAT) | Negative | Separates MAHA from autoimmune hemolysis |
| PT, aPTT, fibrinogen | Usually normal in TTP and HUS, abnormal in DIC | Points toward or away from DIC |
Further tests target the cause. ADAMTS13 activity is sent before plasma therapy begins; a severely reduced level supports TTP. Stool testing for Shiga toxin, kidney function, liver enzymes, a pregnancy test, blood pressure assessment, and autoimmune screening all help narrow the list.
Treatment Options and Management
Treatment of MAHA anemia is treatment of its cause. Supporting the blood count matters, but the red cells will keep fragmenting until the vessel injury is controlled.
Immediate Interventions
- Therapeutic plasma exchange: the cornerstone for suspected TTP. It removes the ADAMTS13 antibody and replaces the missing enzyme, and it is usually started urgently, often before the ADAMTS13 result returns.
- Corticosteroids and rituximab: used in immune TTP to suppress antibody production.
- Caplacizumab: a drug that blocks von Willebrand factor from binding platelets, used alongside plasma exchange in acquired TTP.
- Complement inhibitors: such as eculizumab or ravulizumab for atypical HUS.
- Supportive kidney care: fluids, blood pressure control, and dialysis when needed, especially in Shiga toxin HUS.
Transfusion Considerations
Red cell transfusion is given when anemia causes symptoms or hemoglobin falls very low. Platelet transfusion is generally avoided in TTP unless there is serious bleeding or a procedure is required, because it may feed further clot formation.
Treating Other Causes
DIC is managed by treating sepsis or the underlying illness. Malignant hypertension needs controlled blood pressure lowering. Pregnancy-related MAHA often resolves after delivery, and drug-induced cases require stopping the offending medication. Folic acid is commonly given because active hemolysis increases demand for it.
Outlook and Recovery
With prompt recognition, many patients recover well. Platelet count and LDH are the markers most closely watched during treatment; normalizing values signal that the process is coming under control. Schistocytes gradually disappear from the smear as new, healthy cells replace fragmented ones.
Some conditions can relapse, particularly immune TTP and atypical HUS, so long-term follow-up with a hematologist is standard. Kidney function may need ongoing monitoring after HUS. For a wider look at how these problems fit into blood health, see our guide to hematology and the anemia guide.
When to See a Doctor
Seek emergency care if anemia symptoms appear together with easy bruising, tiny skin spots, confusion, severe headache, reduced urine, or bloody diarrhea. These combinations suggest a thrombotic microangiopathy that needs same-day blood tests and a smear review. Anyone with a known history of TTP or atypical HUS should report new fatigue, bruising, or neurologic symptoms promptly, since relapse is treatable when caught early.
Frequently Asked Questions
Is MAHA anemia the same as TTP?
No. MAHA describes the pattern of red cell fragmentation, while TTP is one specific disease that causes it. HUS, DIC, malignant hypertension, and pregnancy complications can all produce MAHA as well.
What are schistocytes?
Schistocytes are fragments of red blood cells, often shaped like helmets or triangles, seen on a blood smear. Finding them in meaningful numbers is the key laboratory clue that red cells are being mechanically damaged in small vessels.
Can MAHA anemia be cured?
The anemia usually resolves once the underlying cause is controlled. Whether the cause itself is cured depends on the condition; Shiga toxin HUS often does not return, while immune TTP and atypical HUS may need long-term monitoring or maintenance treatment.
Why is the direct antiglobulin test negative in MAHA?
The DAT detects antibodies or complement coating red cells. In MAHA, red cells are destroyed by physical shearing rather than antibody attack, so the test is typically negative, which helps distinguish it from autoimmune hemolytic anemia.
